Related Experiment Video
Updated: May 18, 2026
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Microvascular effect of intracoronary eptifibatide in acute myocardial infarction
Adrian Iancu1, Camelia Ober, Cosmina Ioana Bondor
1'Niculae Stăncioiu' Heart Institute, Cluj-Napoca, Romania.
Insights
Intracoronary eptifibatide did not significantly reduce microvascular obstruction in acute myocardial infarction patients undergoing primary percutaneous coronary intervention after clopidogrel loading. Further research is needed to explore alternative treatments for improving microvascular reperfusion.
Area of Science:
- Cardiology
- Interventional Cardiology
- Vascular Biology
Background:
- Acute myocardial infarction (AMI) remains a leading cause of mortality worldwide.
- Primary percutaneous coronary intervention (PPCI) is the standard reperfusion therapy for AMI.
- Microvascular obstruction (MVO) is a key determinant of infarct size and adverse cardiac outcomes post-AMI.
Purpose of the Study:
- To investigate the efficacy of intracoronary eptifibatide in reducing microvascular obstruction in AMI patients undergoing PPCI.
- To evaluate the impact of eptifibatide on myocardial perfusion and ST-segment resolution.
Main Methods:
- A prospective, randomized trial involving 50 AMI patients with left anterior descending artery occlusion.
- Patients received a 600 mg clopidogrel load before randomization to either an eptifibatide group (EG) or a control group (CG).
- Microvascular reperfusion was assessed using angiography, electrocardiography, and Doppler ultrasonography.
Main Results:
- No significant difference in TIMI myocardial perfusion grade (72% vs. 84%, p=0.31) or ST-segment resolution >70% (32% vs. 40%, p=0.56) between groups.
- Mean diastolic deceleration time did not differ significantly (935.72 ± 252.22 ms in EG vs. 856.36 ± 397.88 ms in CG, p=0.41).
- Multivariate analysis showed no significant influence of eptifibatide on assessed reperfusion parameters.
Conclusions:
- Intracoronary eptifibatide administration did not significantly improve microvascular obstruction in AMI patients pre-treated with clopidogrel undergoing PPCI.
- The findings suggest that additional eptifibatide may not be beneficial in this specific clinical setting.
- Further studies are warranted to identify optimal strategies for mitigating microvascular dysfunction post-AMI.
Objectives:
In this prospective, randomized trial in patients with acute myocardial infarction (AMI) admitted for primary percutaneous coronary intervention (PPCI), loaded with 600 mg clopidogrel, we hypothesized that eptifibatide administered downstream of the coronary occlusion leads to a lower degree of microvascular obstruction compared with no additional eptifibatide.
Methods:
Fifty patients with AMI, loaded with 600 mg of clopidogrel at the first hospital contact, with occlusion of the left anterior descending artery (LAD), were randomized to an eptifibatide group (EG) or a control group (CG). In both groups, stenting was performed after thrombus aspiration. Microvascular reperfusion was assessed by angiography, electrocardiography, and transthoracic Doppler ultrasonography of the LAD.
Results:
TIMI myocardial perfusion grade 2-3 was not different between the EG (72%) and the CG (84%) (p = 0.31). ST segment resolution >70% was similarly detected in both groups (32 vs. 40%; p = 0.56). The mean diastolic deceleration time did not differ significantly between the CG (856.36 ± 397.88 ms) and the EG (935.72 ± 252.22 ms) (p = 0.41). Multivariate logistic regression revealed no significant influence of the treatment with eptifibatide on ST segment resolution (OR 0.47; 95% CI 0.11-2.10, p = 0.32), TIMI myocardial perfusion (OR 0.52; 95% CI 0.10-2.59, p = 0.42), and diastolic deceleration time (OR 0.21; 95% CI 0.03-1.51, p = 0.12).
Conclusions:
In AMI patients loaded with 600 mg of clopidogrel undergoing PPCI, intracoronary administration of eptifibatide does not clearly improve microvascular obstruction.
